Working Group on a New Grand Bargain for Antimicrobial Procurement
June 27, 2022
While there have been high-level commitments from the World Health Assembly, the United Nations General Assembly (UNGA), the G20, and the G7 to tackle AMR, there has yet to be a fundamental change in how we purchase antimicrobials, or an international approach to improving access, fostering innovati...
The ‘Learning at Scale’ Advisory Group
October 08, 2019
Learning outcomes are low and instruction is poor in many countries in the Global South. Improving learning outcomes has proven to be difficult, although the number of successful programs is growing. The effective examples have seldom been implemented at large scale, however; and the large-scale suc...
Incorporating Economics and Modelling in Global Health Goals and Guidelines
November 15, 2017
International organizations influence national-level health sector priorities by affecting how much funding is available for healthcare delivery within countries and setting limits on how that funding is used. They exert particular influence in setting disease-specific targets, developing clinical g...
Working Group on the Future of Global Health Procurement
July 31, 2017
Many low-and lower-middle-income countries currently procure a large portion of their health commodities through centralized, donor-managed procurement mechanisms, and often at subsidized prices or as donations. Over the next several decades, however, the landscape of global health procurement will ...
Drug Resistance Working Group (November 2007 – June 2010)
September 10, 2014
Priority-Setting Institutions for Global Health
September 10, 2014
If you have $200 to spend on health in a developing country, would you vaccinate 10 children against deadly childhood diseases or provide AIDS treatment to one woman to prevent transmission of HIV to her unborn child? Policy makers routinely face such tough budgetary dilemmas with little expert guid...
Value for Money: An Agenda for Global Health Funding Agencies
August 25, 2014
As international commitments become more ambitious and aid resources become increasingly constrained, global health funding agencies are seeking to improve the efficiency and impact of their investments. This growing “value for money” (VfM) agenda aims to reduce costs, increase imp...